CORE--BIOSAMPLE REPOSITORY

核心--BIOSAMPLE存储库

• 批准号: 7142518
• 负责人: Robert C Young
• 金额: $ 7.21万
• 依托单位: FOX CHASE CANCER CENTER
• 依托单位国家: 美国
• 财政年份: 2005
• 资助国家: 美国
• 起止时间: 2005-09-10 至 2010-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7142518
• 关键词: biomedical facility; cancer registry /resource; human tissue; tissue resource /registry

Translational research requires access to appropriately consented and well-characterized human biosamples. Therefore, the Fox Chase Cancer Center (FCCC) established the Biosample Repository Core Facility (BRCF) in 1999/2000 to support this research. The BRCF is a CAP accreditation and CLIA-approved Facility that has two major functions: 1) BRCF staff identifies participants, administers informed consent for blood and tissue use, and collects blood samples and information on personal and family histories of cancer, clinical intervention, clinical outcomes, and lifestyle factors for use in research, and 2) BRCF staff processes and houses human biospecimens obtained through investigator-initiated studies. The FCCC has many funded research Programs which require access to biospecimens from large cohorts of properly consented individuals affected and unaffected with cancer. Programs include: i) clinical studies to assess genetic susceptibility in cancer prone-kindreds, ii) large scale genotyping studies to identify genetic modifiers of cancer risk, iii) pharmacogenomic studies to identify drug response and drug toxicity markers, iv) hormone and immune response studies to determine the role of psychological stress and breast cancer risk, v) smoking cessation studies using genetic modifiers to assess behavioral response, vi) hormone and genotype studies to predict cancer risks, vii) identifying plasma membrane proteins that are selectively expressed in lung or prostate cancer to identify new targets for the development of additional therapeutic monoclonal antibodies, and viii) studies of early detection of cancer by genetic, epigenetic, and proteomic approaches. The BRCF provides a centralized service for accrual, consenting, processing, banking, and/or distribution of human blood samples (e.g., whole blood, plasma, serum, platelet-rich plasma, platelet homogenates, red blood cells, leukocytes, lymphoblastoid cell lines, and DNA) and cancer history data to be utilized in genetic-, epigenetic-, and proteomic-related research. The BRCF currently houses more than 300,000 human biosamples and has served 28 (26 peer-reviewed funded) Fox Chase investigators across 12 Programs and the three Divisions since its inception at the time of previous Core renewal. Ninety-six percent (96%) of the BRCF's use is by peer-reviewed funded investigators.

翻译研究需要获得适当的同意和良好的特征 人体生物样本。因此，狐狸大通癌症中心(Fccc)建立了生物样本 在1999/2000年间建立了储存库核心设施(BRCF)，以支持这项研究。BRCF是一个CAP 认证和CLIA批准的机制，具有两个主要功能：1)BRCF工作人员识别 该中心负责收集血液和组织使用的知情同意书，收集血液样本和癌症个人和家族史、临床干预、临床结果和生活方式因素的信息，用于研究；2)BRCF工作人员处理和存放通过研究人员发起的研究获得的人类生物标本。Fccc有许多资助的研究项目，这些项目需要从受癌症影响和未受影响的适当同意的个人的大队列中获得生物检材。项目包括：i)评估癌症易感性的临床研究；ii)大规模基因分型研究以确定癌症风险的遗传修饰因素；iii)药物基因组学研究以确定药物反应和药物毒性标记物；iv)激素和免疫反应研究以确定心理应激和乳腺癌风险的作用；v)使用遗传修饰因素进行戒烟研究以评估行为反应；vi)激素和基因研究以预测癌症风险；vii)鉴定在肺癌或前列腺癌中选择性表达的质膜蛋白以确定开发额外的治疗性单抗的新靶点；以及)通过遗传学、表观遗传学、和蛋白质组学方法。BRCF为人类血液样本(例如，全血、血浆、血清、富含血小板的血浆、血小板匀浆、红细胞、白细胞、淋巴母细胞系和DNA)和癌症病史数据的积累、同意、处理、储存和/或分配提供集中服务，用于遗传学、表观遗传学和蛋白质组相关研究。BRCF目前拥有30多万个人体生物样本，自上次核心更新时成立以来，已为12个项目和三个部门的28名福克斯大通调查人员(26名同行审查资助)提供了服务。96%(96%)的BRCF是由同行评审资助的调查人员使用的。